Latest News
France Weighs €6B Pension Savings but No Final Plan Yet
France aims for €6 billion in pension savings but hasn't decided how. Bond market pressure grows as fiscal challenges persist.
Capitals Lock Up Leonard for 8 Years, $84M Ahead of NHL Rule Change
The Capitals signed Ryan Leonard to an 8-year, $84M extension, locking in an extra year before NHL rules change. The deal averages $10.5M annually.
XRP Ledger Lending Upgrade Still Inactive; Bank Control Claims Unfounded
The XRP Ledger's LendingProtocol upgrade is not yet live, and claims that it gives banks control are exaggerated. Validators still govern the network.
Enbridge's C$3B Share Sale Raises C$264M DCF Hurdle
Enbridge's C$3B share sale adds 44.7M shares, requiring ~C$264M in annual DCF to offset dilution. The market's calm reaction suggests absorption, but the real test lies ahead.
Take-Two Escalates GTA VI Leak Hunt with Second Discord Subpoena
Take-Two Interactive obtained a second federal subpoena for Discord in its GTA VI leak investigation. The move adds legal pressure but doesn't confirm a leaker's identity.
Vera Bradley's Quarterly Profit Boosted by Tariff Refund
Vera Bradley swung to a quarterly profit, but a $7.7 million tariff refund fueled most of the margin expansion. Direct sales rose 8%.
Forgent's $3B Backlog Drives 13% Stock Surge Despite Negative FCF
Forgent Power Solutions (FPS) surged 12.67% after reporting $1.503B in Q4 bookings and a $3B backlog, but full-year free cash flow was negative $6.8M.
5E Advanced Materials' Searles Valley Buy: Stock, Debt, and Bridge Financing
5E Advanced Materials' acquisition of Searles Valley involves a mix of cash, stock, and debt, with a $10M bridge loan. The deal's value fluctuates with FEAM's share price.
GTA VI Voice Actor Confirmed, But Take-Two's $8.2B Outlook Hinges on Launch
Stephen Root confirms he voices Brian Heder in GTA VI, but Take-Two's stock dipped as the market's focus remains on the November 19 launch and fiscal 2027 targets.
Vera's TRUTAKNA Cuts Kidney Decline Risk by 76% in Phase 3 Trial
Vera Therapeutics announced that TRUTAKNA reduced kidney progression risk by 76% in a confirmatory Phase 3 trial, sending shares up 9.4% in premarket trading.